Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Jin Li, Shukui Qin, Jianming Xu, +31

Journal of Clinical Oncology

The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

Feng‐Hua Wang, Lin Shen, Jin Li, +19

Cancer Communications

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Jin Li, Shukui Qin, Rui‐Hua Xu, +17

The Lancet Oncology

OncologyGastrointestinal OncologyCancer ManagementClinical TrialsColorectal Cancer +6

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

Timothy Price, Marc Peeters, Tae Won Kim, +9

The Lancet Oncology

OncologyChemotherapy-refractory Wild-type KrasColorectal CancerPathologyMetastatic Colorectal Cancer +7

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer

Xichun Hu, Jian Zhang, Binghe Xu, +14

International Journal of Cancer

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial

Shukui Qin, Jin Li, Liwei Wang, +24

Journal of Clinical Oncology

Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

Lin Shen, Jin Li, Jianming Xu, +13

Gastric Cancer

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.

J. Randolph Hecht, Yung‐Jue Bang, Shukui Qin, +16

Journal of Clinical Oncology

Tumor BiologyOncologyEsophageal CancerGastrointestinal OncologyGastroesophageal Adenocarcinoma +13

Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer

Xiaowei Zhang, Rui‐Xi Hua, Xiaofeng Wang, +8

Oncotarget

Adult Stem CellPathologyCancer BiologyTumor BiologyStem-like Cells +14

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang, +13

Journal of Clinical Oncology

ImmunologyGastroenterologyPathologyBema ArmPharmacotherapy +15